Recombinant interferon-α may retard progression of early primary myelofibrosis: A preliminary report

Blood

Volumn 117, Issue 24, 2011, Pages 6669-6672

  Silver, Richard T ^a   Vandris, Katherine ^a   Goldman, Joshua J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ANEMIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; DISEASE COURSE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; HYPERTHYROIDISM; HYPOCALCEMIA; LEUKOPENIA; LIVER FUNCTION TEST; MALE; MYALGIA; MYELOFIBROSIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 79959232873     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-11-320069     Document Type: Article

References (25)

1. Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood. 2009; 113(22):5394-5400.
2. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
3. Vannucchi AM. From pallation to targeted therapy in myelofibrosis. N Engl J Med. 2010;363(12): 1180-1182.
4. Kröger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia. 2008;22(3):474-486. (Pubitemid 351386717)
5. Silver RT. Treatment of polycythemia vera. Semin Thromb Hemost. 2006;32(4):437-442.
6. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-α. Cancer. 2006;107(3):451-458. (Pubitemid 44107203)
7. Kiladjian JJ, Cassinat B, Tulure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108(6):2037-2040. (Pubitemid 44395018)
8. Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009; 27(32):5418-5424.
9. Lu M, ZhangW, Li Y, et al. Interferon-alpha targets JAK2F617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol. 2010;38(6):472-480.
10. Hasselbalch HC. Myelofibrosis with myeloid metaplasia. The advanced phase of an untreated disseminated hematological cancer: time to change our therapeutic attitude with early upfront treatment? Leuk Res. 2009;33(1):11-18.
11. Bachleitner-Hofmann T, Gisslinger H. The role of interferon-alpha in the treatment of idiopathic myelofibrosis. Ann Hematol. 1999;78(12):533-538. (Pubitemid 30009354)
12. Ianotto JC, Kiladjian JJ, Demory JL, et al. PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myé loprolifératifs (FIM). Br J Haematol. 2009;146(2):223-225.
13. Jabbour E, Kantarjian H, Cortes J, et al. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer. 2007;110(9):2012-2018. (Pubitemid 350036861)
14. Silver RT, Vandris K. Recombinant interferon alpha (rIFNα-2b) may retard progression of early primary myelofibrosis [letter]. Leukemia. 2009; 23(7):1366-1369.
15. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097.
16. Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol. 1979;43(2):185-190. (Pubitemid 10243277)
17. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
18. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708.
19. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006; 108(5):1497-1503. (Pubitemid 44316114)
20. Chen Q, Lu P, Jones AV, Cross NC, Silver RT, Wang YL. Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2V617F mutation in chronic myeloproliferative disorders. J Mol Diagn. 2007;9(2):272-276. (Pubitemid 47305096)
21. Jones AV, Silver RT, Waghorn K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood. 2006;107(8):3339-3341.
22. Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009; 113(20):4829-4833.
23. Hussein K, PardananiAD, Van Dyke DL, Hanson CA, Tefferi A. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood. 2010;115(3):496-499.
24. Tam CS, Abruzzo LV, Lin KI, et al. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood. 2009;113(18):4171-4178.
25. Schaub FX, Jäger R, Looser R, et al. Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F. Blood. 2009;113(9): 2022-2027.